PropertyValue
?:abstract
  • : This article highlights recent guidance from the National Institute for Health and Care Excellence (NICE). It provides an overview of the COVID-19 rapid guidance produced since March 2020, along with an account of how the organization adapted during the pandemic, developing resources to guide practice with the limited time and evidence available. The growing COVID-19 evidence base is also considered, with reference to international initiatives supporting production of the best possible information to guide the global pandemic response. WHAT’S NEW? Since March 2020, the NICE has developed 21 rapid guidelines with NHS England and NHS Improvement (NHSE&I) and a cross-speciality clinical group, supported by specialist societies and royal colleges. The 21 guidelines can be summarized into three groups—managing symptoms and complications, managing conditions that increase risk, and providing services during the pandemic. The rapid guidelines are part of a suite of rapid resources, including innovative technology briefings, shared learning examples and rapid evidence summaries, such as that for Vitamin D in COVID-19 (ES28).
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1093/pubmed/fdaa184
?:journal
  • J_Public_Health_(Oxf)
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/d0db6831e9921ae84b2a9b01645564aa75377138.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7665661.xml.json
?:pmcid
?:pmid
?:pmid
  • 33150447.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Spotlight on COVID-19 rapid guidance: NICE’s experience of producing rapid guidelines during the pandemic
?:type
?:year
  • 2020-11-05

Metadata

Anon_0  
expand all